Bristow Group VTOL Q1 2026 Earnings Earnings Miss Weighs on Investor Sentiment Dianthus Therapeutics Q1 2026 Earnings EPS Beat Driven by Cost Discipline Yet Shares Slip EPM Q1 2026 Earnings Deep EPS Miss Punishes Stock as Revenue Details Remain Unreported CHDN Q1 2026 Earnings EPS Beats Estimates by 182 Stock Edges Lower HY Q1 2026 Earnings Narrowing Losses as Cost Initiatives Gain Traction C4 Therapeutics Q1 2026 Earnings Strong EPS Beat Amid Continued Pipeline Progress